Group 1 - The company has received a registration notice from the trading association, approving the registration of its medium-term notes [1] - The registered amount is 1 billion yuan, and the registration quota is valid for two years from the date of the notice [1] - Industrial Bank Co., Ltd. is the lead underwriter for the issuance of the medium-term notes [1] Group 2 - The company plans to issue the medium-term notes in phases based on market conditions and the requirements of the notice [1] - The company will fulfill its information disclosure obligations in a timely manner [1]

证券代码：301301 证券简称：川宁生物 公告编号：2025-037 伊犁川宁生物技术股份有限公司 关于中期票据获准注册的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 伊犁川宁生物技术股份有限公司（简称"公司"）分别于 2025 年 4 月 18 日召开的第二届董事会第九次会议及 2025 年 5 月 13 日召开的 2024 年年度股东 大会审议通过了《关于公司及所属子公司发行非金融企业债务融资工具的议案》， 同意公司及子（分）公司向中国银行间市场交易商协会（简称"交易商协会"） 申请注册发行非金融企业债务融资工具，发行品种包括但不限于短期融资券、中 期票据、中小企业集合票据、超短期融资券等相关监管部门认可的类型，其中不 受交易商协会注册额度限制的债务融资工具，每一种类产品的注册总额不超过 10 亿元。具体情况详见公司于 2025 年 4 月 22 日在中国证券监督管理委员会指 定的创业板信息披露网站巨潮资讯网（http://www.cninfo.com.cn）披露的相关公 告。 近日，公司收到交易商协会出具的《接受注册通知书》（中市协注〔2025 ...

Group 1 - The core viewpoint of the article highlights the growth of industrial enterprises in the Xinjiang Uygur Autonomous Region, with a total of 5,381 enterprises reported from January to July 2025, marking an increase of 465 enterprises compared to the same period last year, representing a year-on-year growth of 9.46% [1][1][1] - The report indicates that the number of industrial enterprises in Xinjiang accounts for 1.03% of the national total [1][1][1] - The data presented is sourced from the National Bureau of Statistics and organized by Zhiyan Consulting, a leading industry consulting firm in China [1][1][1] Group 2 - The article references various listed companies related to the industrial sector, including Guanghui Energy, New Natural Gas, and others, indicating potential investment opportunities [1][1][1] - Zhiyan Consulting has been engaged in industry research for over a decade, providing comprehensive industry research reports, business plans, feasibility studies, and customized services [1][1][1] - The report titled "2025-2031 China Industrial Cloud Industry Market Deep Assessment and Investment Opportunity Forecast" is mentioned, suggesting a focus on future market trends and investment potential [1][1][1]

3、本公告中百分比例均保留 4 位小数，若其各分项数值之和与合计数值存 在尾差，均为四舍五入原因造成。 一、会议召开和出席情况 （一）召开情况 1、股东大会届次：2025 年第二次临时股东大会 证券代码：301301 证券简称：川宁生物 公告编号：2025-036 伊犁川宁生物技术股份有限公司 2025年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会不涉及变更以往股东大会已通过的决议。 2、股东大会的召集人：公司董事会 3、股东大会的主持人：董事长刘革新先生 4、会议召开时间： （1）现场会议召开时间：2025 年 9 月 10 日 15:00 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为：2025 年 9 月 10 日 9:15-9:25、9:30-11:30 和 13:00-15:00 期间任意时间；通 过深圳证券交易所互联网投票系统投票的具体时间为 2025 年 9 月 10 日 9:15-15:00 期间任意时间。 5、现场会议 ...

四川省成都市高新区天府大道北段 966 号天府国际金融中心南塔 25 层-26 层 邮编：610041 25-26/F, South Tower of Tianfu International Finance Center, 966 North Tianfu Avenue, High-tech Zone, Chengdu, Sichuan 610041, P. R. China 电话/Tel : +86 28 6208 8001 传真/Fax : +86 28 6208 8111 www.zhonglun.com 北京中伦（成都）律师事务所 关于伊犁川宁生物技术股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：伊犁川宁生物技术股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共 和国证券法》（以下简称"《证券法》"）及《上市公司股东会规则》等法律、法规 及规范性文件的规定，北京中伦（成都）律师事务所（以下简称"本所"）指派 律师出席了伊犁川宁生物技术股份有限公司（以下简称"公司"）2025 年第二次 临时股东大会（以下简称"本次股东大会"），并对本次股东大会的相关事 ...

Core Viewpoint - The company expects a stable long-term demand for antibiotics despite a short-term decline in market demand compared to the previous year [1] Antibiotic Intermediates Overview - The market demand for thiocyanate erythromycin remains stable, with a balanced supply and demand [1] - Domestic and international demand for cephalosporin intermediates has decreased year-on-year, but the absence of new large-scale production capacity has allowed the company to optimize production allocation, keeping market prices stable [1] - The demand for penicillin intermediates has declined due to changes in disease prevalence and the introduction of new production capacity, leading to a significant price drop; however, the company anticipates a gradual stabilization of prices as some outdated capacities are shut down and Indian production capacity does not meet expectations [1]

Group 1 - The grain concept sector experienced a decline of 1.01%, ranking among the top declines in the concept sectors, with notable declines in stocks such as Yalian Development, QuanYin High-Tech, and Wanxiang DeNong [1] - Among the grain concept stocks, 39 experienced net outflows from main funds, with a total outflow of 504 million yuan, led by Beidahuang with a net outflow of 57.84 million yuan [1] - The top gainers in the grain concept sector included COFCO Technology, Lianhua Holdings, and Ruimaotong, with increases of 0.81%, 0.78%, and 0.66% respectively [1] Group 2 - The top concept sectors for gains included Copper Cable High-Speed Connection with a rise of 5.61%, and Co-Packaged Optics (CPO) with a rise of 5.13%, while the Transgenic sector fell by 1.81% [1] - The grain concept sector saw significant net outflows, with six stocks experiencing outflows exceeding 30 million yuan, including ChuanNing Biological and Lianhua Holdings [1][2] - The main funds saw inflows in stocks such as Ruimaotong, Guangyu Group, and JiaHua Shares, with inflows of 5.29 million yuan, 3.44 million yuan, and 2.75 million yuan respectively [2]

Core Viewpoint - The financial performance of Chuaning Bio for the first half of 2025 shows significant declines in revenue and net profit, indicating challenges in the current market environment [2][3]. Financial Performance Summary - The company reported a revenue of 2.35 billion yuan, a decrease of 26.50% compared to the same period last year [3]. - Net profit attributable to shareholders was 455 million yuan, down 40.64% year-on-year [3]. - The net profit after deducting non-recurring gains and losses was 456 million yuan, reflecting a 40.38% decline [3]. - Basic earnings per share were 0.20 yuan, a decrease of 41.18% from the previous year [3]. - Cash flow from operating activities decreased by 49.32%, amounting to 391 million yuan [3]. - Total assets at the end of the reporting period were 10.16 billion yuan, down 3.74% from the previous year [3]. Strategic Focus and Future Directions - The company plans to enhance its core competitiveness through four strategic directions: 1. Reforming traditional antibiotic intermediates and Q10 through synthetic biology, utilizing gene editing and metabolic engineering to improve product efficacy and reduce production costs [4]. 2. Enhancing and cost-reducing existing products like red myrtle alcohol and squalene through optimization of strains and fermentation processes [4]. 3. Efficient biological utilization of C1/C2 resources, focusing on sustainable production of single-cell proteins and specialty chemicals [4]. 4. Developing larger-scale amino acids and vitamins [5]. Main Business and Product Overview - Chuaning Bio operates in the pharmaceutical manufacturing sector, focusing on "biological fermentation" and "synthetic biology" as dual driving strategies [5]. - The company has invested over 8 billion yuan in its fermentation projects, with a total production capacity of approximately 16,000 tons per year [6]. - Key products include thiocyanate erythromycin, cephalosporin intermediates, penicillin intermediates, and coenzyme Q10 [6]. - The synthetic biology project, with an investment of 1 billion yuan, has multiple products in production, making the company one of the few in the industry to complete the entire process from selection to large-scale production [6].

Core Viewpoint - The financial performance of Chuaning Bio (301301) for the first half of 2025 shows significant declines in revenue and net profit, indicating challenges in the market and operational efficiency [1]. Financial Performance Summary - Total revenue for the first half of 2025 was 2.349 billion yuan, a decrease of 26.5% year-on-year [1]. - Net profit attributable to shareholders was 455 million yuan, down 40.64% compared to the previous year [1]. - The gross profit margin improved slightly to 35.87%, an increase of 1.57% year-on-year, while the net profit margin fell to 19.36%, a decrease of 19.29% [1]. - Total expenses (selling, administrative, and financial) amounted to 139 million yuan, representing 5.94% of revenue, an increase of 55.83% year-on-year [1]. - Earnings per share decreased to 0.20 yuan, down 41.18% year-on-year [1]. Cash Flow and Investment Summary - The net cash flow from operating activities decreased by 49.32%, attributed to lower product prices and reduced collections [5]. - The net cash flow from investing activities increased by 35.87%, due to reduced payments for fixed assets and investments [2]. - The net increase in cash and cash equivalents dropped significantly by 274.54%, primarily due to decreased collections and increased dividend payments [5]. Market and Product Insights - The overall demand for the company's main products has declined, impacting sales and pricing [3]. - The price of the main intermediate products has remained stable, with slight increases in some areas, while others have seen price drops due to reduced market demand [3]. - The company is focusing on enhancing its core competencies in traditional antibiotic intermediates and exploring new product lines in synthetic biology [6][7][8]. Future Outlook - The company anticipates a challenging year due to the impact of declining penicillin prices, but expects improvements in the fourth quarter with increased market demand [14]. - The release of synthetic biology products is expected to enhance overall performance and profitability in 2026 [14].

Core Viewpoint - The recent financial report of Chuaning Bio (301301) indicates a significant decline in both revenue and net profit for the first half of 2025, with net profit down by 40.64% year-on-year and total revenue down by 26.5% year-on-year, reflecting challenges in the market and operational performance [1]. Financial Performance Summary - Total revenue for the first half of 2025 was 2.349 billion yuan, a decrease of 26.5% compared to 3.195 billion yuan in the same period of 2024 [1]. - Net profit attributable to shareholders was 455 million yuan, down 40.64% from 766 million yuan in the previous year [1]. - Gross margin improved slightly to 35.87%, up 1.57% year-on-year, while net margin fell to 19.36%, down 19.29% year-on-year [1]. - Total expenses (selling, administrative, and financial) amounted to 139 million yuan, representing 5.94% of revenue, an increase of 55.83% year-on-year [1]. - Earnings per share decreased to 0.20 yuan, down 41.18% from 0.34 yuan in the previous year [1]. Cash Flow and Asset Management - Cash and cash equivalents decreased by 25.71%, attributed to reduced collections and increased dividend payments [1]. - Operating cash flow per share fell to 0.18 yuan, a decline of 49.38% year-on-year [1]. - Accounts receivable increased by 65% to 1.028 billion yuan, indicating challenges in cash collection [1][2]. Cost and Expense Analysis - Sales expenses rose by 16.59% due to increased promotional costs for new products [9]. - Management expenses increased by 33.51% as a result of trials for new product lines [9]. - Financial expenses decreased by 42.84% due to reduced interest payments [9]. Investment and R&D Focus - R&D investment surged by 138.47%, reflecting a commitment to new product development [9]. - The company plans to focus on enhancing traditional antibiotic intermediates and developing new biomanufacturing processes utilizing C1/C2 resources [13][14]. Market Outlook and Product Strategy - The company anticipates a challenging year due to the impact of declining prices in the penicillin market, but expects improvement in the fourth quarter with increased demand [20]. - The sales of synthetic biology products are projected to grow as production capacity is adjusted and released [11]. - The company is also exploring opportunities in Kazakhstan but has decided to postpone expansion due to various risks [11].